The “Innovation Partnership for a Roadmap on Vaccines in Europe” (IPROVE) has launched on 16 March a strategic roadmap setting out a vision for vaccine research and innovation in Europe. The roadmap will inform strategic decisions on the priorities for future vaccine investment in innovation and technological development at European Union and individual Member State level. Through a bottom-up approach involving all key stakeholders in the European vaccine field, the strategy aims to overcome fragmentation and remove bottlenecks to translation of breakthrough research into innovative vaccines.
With her doctoral research, TU Delft doctoral candidate Ahd Hamidi has made a major contribution to developing an innovative, scalable, affordable version of the Haemophilus influenzae (Hib) vaccine developed by Intravacc. This low-cost vaccine has now been used to protect 200 million children worldwide against Hib diseases such as meningitis, pneumonia, sepsis and otitis media. Hamidi has defended her dissertation at TU Delft on Thursday 3 March.
Pseudo viruses (PVs) are non-infectious particles with the ‘core’ of one virus and the envelope glycoprotein of the study virus. PVs can be used as a fast, safe and effective screening tool for the prevalence of viruses in suspected infectees (www.viralpseudotypeunit.info). Intravacc supports a recent grant application from Dr Simon Scott, Dr Nigel Temperton (University of Kent) and Dr Edward Wright (University of Westminster) to develop a lyophilized, Ebola Pseudovirus- based Antibody neutralization kit for commercial use. By contributing to the project with its lyophilization and scale-up knowledge Intravacc aims to contribute to the fight against Ebola, a disease featured on the current WHO priority disease list.